Glucocerebrosidase Activity, Cathepsin D and Monomeric α-synuclein Interactions in a Stem Cell Derived Neuronal Model of a PD Associated GBA1 Mutation

Overview

Journal Neurobiol Dis

Specialty Neurology

Date 2019 Oct 22

PMID 31634558

Citations 27

Authors

Shi-Yu Yang

Matthew Gegg

David Chau

Anthony Schapira

Affiliations

Soon will be listed here.

Abstract

The presence of GBA1 gene mutations increases risk for Parkinson's disease (PD), but the pathogenic mechanisms of GBA1 associated PD remain unknown. Given that impaired α-synuclein turnover is a hallmark of PD pathogenesis and cathepsin D is a key enzyme involved in α-synuclein degradation in neuronal cells, we have examined the relationship of glucocerebrosidase (GCase), cathepsin D and monomeric α-synuclein in human neural crest stem cell derived dopaminergic neurons. We found that normal activity of GCase is necessary for cathepsin D to perform its function of monomeric α-synuclein removal from neurons. GBA1 mutations lead to a lower level of cathepsin D protein and activity, and higher level of monomeric α-synuclein in neurons. When GBA1 mutant neurons were treated with GCase replacement or chaperone therapy; cathepsin D protein levels and activity were restored, and monomeric α-synuclein decreased. When cathepsin D was inhibited, GCase replacement failed to reduce monomeric α-synuclein levels in GBA1 mutant neurons. These data indicate that GBA1 gene mutations increase monomeric α-synuclein levels via an effect on lysosomal cathepsin D in neurons.

Citing Articles

Evolving Landscape of Parkinson's Disease Research: Challenges and Perspectives.

Tenchov R, Sasso J, Zhou Q ACS Omega. 2025; 10(2):1864-1892.

PMID: 39866628 PMC: 11755173. DOI: 10.1021/acsomega.4c09114.

Consensus Guidance for Genetic Counseling in GBA1 Variants: A Focus on Parkinson's Disease.

Vieira S, Mezabrovschi R, Toffoli M, Del Pozo S, Menozzi E, Mullin S Mov Disord. 2024; 39(12):2144-2154.

PMID: 39258449 PMC: 11657020. DOI: 10.1002/mds.30006.

-Associated Parkinson's Disease Is a Distinct Entity.

Skrahin A, Horowitz M, Istaiti M, Skrahina V, Lukas J, Yahalom G Int J Mol Sci. 2024; 25(13).

PMID: 39000225 PMC: 11241486. DOI: 10.3390/ijms25137102.

The Role of Alpha-Synuclein in Synucleinopathy: Impact on Lipid Regulation at Mitochondria-ER Membranes.

Barbuti P, Guardia-Laguarta C, Yun T, Chatila Z, Flowers X, Santos B bioRxiv. 2024; .

PMID: 38948777 PMC: 11212931. DOI: 10.1101/2024.06.17.599406.

Genetic modifiers of synucleinopathies-lessons from experimental models.

Lee R, Koh T Oxf Open Neurosci. 2024; 2:kvad001.

PMID: 38596238 PMC: 10913850. DOI: 10.1093/oons/kvad001.

References

Migdalska-Richards A, Daly L, Bezard E, Schapira A . Ambroxol effects in glucocerebrosidase and α-synuclein transgenic mice. Ann Neurol. 2016; 80(5):766-775. PMC: 5132106. DOI: 10.1002/ana.24790. View

Zhao F, Bi L, Wang W, Wu X, Li Y, Gong F . Mutations of glucocerebrosidase gene and susceptibility to Parkinson's disease: An updated meta-analysis in a European population. Neuroscience. 2016; 320:239-46. DOI: 10.1016/j.neuroscience.2016.02.007. View

Neumann J, Bras J, Deas E, OSullivan S, Parkkinen L, Lachmann R . Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease. Brain. 2009; 132(Pt 7):1783-94. PMC: 2702833. DOI: 10.1093/brain/awp044. View

Schondorf D, Aureli M, McAllister F, Hindley C, Mayer F, Schmid B . iPSC-derived neurons from GBA1-associated Parkinson's disease patients show autophagic defects and impaired calcium homeostasis. Nat Commun. 2014; 5:4028. DOI: 10.1038/ncomms5028. View

Magalhaes J, Gegg M, Migdalska-Richards A, Doherty M, Whitfield P, Schapira A . Autophagic lysosome reformation dysfunction in glucocerebrosidase deficient cells: relevance to Parkinson disease. Hum Mol Genet. 2016; 25(16):3432-3445. PMC: 5179940. DOI: 10.1093/hmg/ddw185. View

Burre J, Sharma M, Tsetsenis T, Buchman V, Etherton M, Sudhof T . Alpha-synuclein promotes SNARE-complex assembly in vivo and in vitro. Science. 2010; 329(5999):1663-7. PMC: 3235365. DOI: 10.1126/science.1195227. View

Parnetti L, Paciotti S, Eusebi P, Dardis A, Zampieri S, Chiasserini D . Cerebrospinal fluid β-glucocerebrosidase activity is reduced in parkinson's disease patients. Mov Disord. 2017; 32(10):1423-1431. DOI: 10.1002/mds.27136. View

Fonteh A, Harrington R, Huhmer A, Biringer R, Riggins J, Harrington M . Identification of disease markers in human cerebrospinal fluid using lipidomic and proteomic methods. Dis Markers. 2006; 22(1-2):39-64. PMC: 3851111. DOI: 10.1155/2006/202938. View

Davidson W, Jonas A, Clayton D, George J . Stabilization of alpha-synuclein secondary structure upon binding to synthetic membranes. J Biol Chem. 1998; 273(16):9443-9. DOI: 10.1074/jbc.273.16.9443. View

10.

Gegg M, Burke D, Heales S, Cooper J, Hardy J, Wood N . Glucocerebrosidase deficiency in substantia nigra of parkinson disease brains. Ann Neurol. 2012; 72(3):455-63. PMC: 3638323. DOI: 10.1002/ana.23614. View

11.

McNeill A, Magalhaes J, Shen C, Chau K, Hughes D, Mehta A . Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells. Brain. 2014; 137(Pt 5):1481-95. PMC: 3999713. DOI: 10.1093/brain/awu020. View

12.

Balestrino R, Schapira A . Glucocerebrosidase and Parkinson Disease: Molecular, Clinical, and Therapeutic Implications. Neuroscientist. 2018; 24(5):540-559. DOI: 10.1177/1073858417748875. View

13.

Kurzawa-Akanbi M, Hanson P, Blain P, Lett D, McKeith I, Chinnery P . Glucocerebrosidase mutations alter the endoplasmic reticulum and lysosomes in Lewy body disease. J Neurochem. 2012; 123(2):298-309. PMC: 3494984. DOI: 10.1111/j.1471-4159.2012.07879.x. View

14.

Rocha E, Smith G, Park E, Cao H, Brown E, Hayes M . Glucocerebrosidase gene therapy prevents α-synucleinopathy of midbrain dopamine neurons. Neurobiol Dis. 2015; 82:495-503. DOI: 10.1016/j.nbd.2015.09.009. View

15.

Yang S, Beavan M, Chau K, Taanman J, Schapira A . A Human Neural Crest Stem Cell-Derived Dopaminergic Neuronal Model Recapitulates Biochemical Abnormalities in GBA1 Mutation Carriers. Stem Cell Reports. 2017; 8(3):728-742. PMC: 5355624. DOI: 10.1016/j.stemcr.2017.01.011. View

16.

Heinrich M, Wickel M, Schneider-Brachert W, Sandberg C, Gahr J, Schwandner R . Cathepsin D targeted by acid sphingomyelinase-derived ceramide. EMBO J. 1999; 18(19):5252-63. PMC: 1171596. DOI: 10.1093/emboj/18.19.5252. View

17.

Crabtree D, Dodson M, Ouyang X, Boyer-Guittaut M, Liang Q, Ballestas M . Over-expression of an inactive mutant cathepsin D increases endogenous alpha-synuclein and cathepsin B activity in SH-SY5Y cells. J Neurochem. 2013; 128(6):950-61. PMC: 3951679. DOI: 10.1111/jnc.12497. View

18.

Kilpatrick B, Magalhaes J, Beavan M, McNeill A, Gegg M, Cleeter M . Endoplasmic reticulum and lysosomal Ca²⁺ stores are remodelled in GBA1-linked Parkinson disease patient fibroblasts. Cell Calcium. 2015; 59(1):12-20. PMC: 4751977. DOI: 10.1016/j.ceca.2015.11.002. View

19.

Mazzulli J, Xu Y, Sun Y, Knight A, McLean P, Caldwell G . Gaucher disease glucocerebrosidase and α-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell. 2011; 146(1):37-52. PMC: 3132082. DOI: 10.1016/j.cell.2011.06.001. View

20.

Brockmann K, Srulijes K, Hauser A, Schulte C, Csoti I, Gasser T . GBA-associated PD presents with nonmotor characteristics. Neurology. 2011; 77(3):276-80. DOI: 10.1212/WNL.0b013e318225ab77. View